Compounds for inhibition of alpha 4 beta 7 integrin

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

X 1 and X 2 are each independently selected from CR 10 and N;

X 3 and X 5 are each independently selected from NR 11 , O, S, C(O), and C(R 10 ) 2 ;

each X 4 is independently selected from NR 11 , O, S, C(O), and C(R 10 ) 2 ;

R 1 is selected from -L-A 1 , -L-A 2 , -L-A 3 , and -L-A 4 ;

L is selected from a bond, —O—, —O—C(O)—*, —NH—, —C(O)—N(H)—*, and —N(H)—C(O)—*; wherein * indicates a point of attachment of L to A 1 , A 2 , A 3 , or A 4 ;

A 1 is C 6-10 aryl optionally substituted with one to six R a ;

A 2 is 5-10 membered heteroaryl containing one to five heteroatoms independently selected from S, N, and O, and optionally one or two C(O); wherein A 2 is optionally substituted with one to six R a ;

A 3 is 5-10 membered cycloalkyl or 5-14 membered heterocyclyl; wherein A 3 is optionally substituted with one to six R a ; and

A 4 is —NR a1 R a2 ;

wherein each R a is independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 1-6 haloalkoxyl, —S(O) m —C 1-6 alkyl, C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C 1-4 alkylene-C 3-8 cycloalkyl, —O-phenyl, and —O—C 3-8 cycloalkyl;

each C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 1-6 haloalkoxyl, and —S(O) m —C 1-6 -alkyl of R a are optionally substituted with one to three R a3 ; wherein each R a 3 is independently selected from hydroxyl, cyano, —NR a1 R a2 , C 1-6 alkoxyl, C 3-8 cycloalkyl, phenyl, and 3-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, phenyl, and 3-6 membered heterocyclyl of R a3 is independently optionally substituted with one to three R a4 ; wherein each R a4 is independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxyl, C 1-6 haloalkoxyl, C 3-8 cycloalkyl, and 3-6 membered heterocyclyl; and

each C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, —O-(3-6 membered heterocyclyl), —O—C 1-4 alkylene-C 3-8 cycloalkyl, —O-phenyl, and —O—C 3-8 cycloalkyl of R a is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxyl, and C 1-6 haloalkoxyl;

each R 2 , R 3 , R 4 , R 5 , and R 6 is independently selected from H, halo, cyano, hydroxyl, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-8 haloalkyl, C 1-8 haloalkoxyl, —NR b1 R b2 , —R b3 S(O) m R b4 , —S(O) m R b4 , —NR b1 S(O) v R b4 , —COOR b1 , —CONR b1 R b2 , —NR b1 COOR b2 , —NR b1 COR b4 , —R b3 NR b1 R b2 , —S(O) v NR b1 R b2 , C 3-12 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-12 membered heterocyclyl;

each C 2-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxyl, C 1-8 haloalkyl, and C 1-8 haloalkoxyl of R 2 , R 3 , R 4 , R 5 , and R 6 is independently optionally substituted with one to two R c ; wherein each R c is independently selected from azido, oxo, cyano, halo, hydroxyl, —NR a1 R a2 , C 1-4 alkoxyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R c is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-6 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl;

each C 6-10 aryl and 5-6 membered heteroaryl of R 2 , R 3 , R 4 , R 5 , and R 6 is independently optionally substituted with one to five R b ; and

each C 3-12 cycloalkyl and 3-12 membered heterocyclyl of R 2 , R 3 , R 4 , R 5 , and R 6 is independently optionally substituted with one to six groups independently selected from ═CR b1 R b2 , and R b ;

wherein each R b is independently selected from azido, cyano, halo, hydroxyl, —NR a1 R a2 , C 1-6 alkyl, C 1-8 haloalkyl, C 1-6 alkoxyl, C 3-6 cycloalkyl, C 3-6 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocycly; wherein each C 3-6 cycloalkyl, C 3-6 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R b is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl;

each R b1 and R b2 is independently selected from H, C 1-8 alkyl, C 1-8 haloalkyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl;

each C 1-8 alkyl and C 1-6 haloalkyl of R b1 and R b2 is optionally substituted with one to two R b5 ; and

each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 3-8 membered heterocyclyl of R b1 and R b2 is independently optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-8 alkyl, C 1-8 haloalkyl, C 1-6 alkoxyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl;

R b3 is C 1-4 alkylene;

R b4 is selected from C 1-4 alkyl, C 1-4 haloalkyl, C 3-6 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 1-4 alkyl, C 1-4 haloalkyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and the 4-6 membered heterocyclyl of R b4 is optionally substituted with one to three R b6 ;

each R b5 is independently selected from cyano, hydroxyl, C 1-4 alkoxyl, C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl; wherein each C 3-8 cycloalkyl, C 6-10 aryl, 5-6 membered heteroaryl, and 4-6 membered heterocyclyl of R b5 is optionally substituted with one to three groups independently selected from halo, cyano, hydroxyl, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and phenyl; and

each R b6 is independently selected from halo, cyano, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl; wherein each C 3-6 cycloalkyl, 4-6 membered heterocyclyl, and 5-6 membered heteroaryl of R b6 is independently optionally substituted with one to three groups independently selected from halo, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, and C 1-4 alkoxyl; or

R 2 and R 3 , R 3 and R 4 , or R 5 and R 6 together with the atoms to which they are attached may form a C 1-6 aryl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, or 5-6 membered heterocyclyl;

wherein each C 6-10 aryl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, or 5-6 membered heterocyclyl is optionally substituted with one to three groups independently selected from halo, cyano, —NR a1 R a2 , C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, C 3-8 cycloalkyl, 3-6 membered heterocyclyl, C 6-10 -aryl, 5-6 membered heteroaryl, C 1-4 alkylene-C 3-8 cycloalkyl, C 1-4 alkylene-C 6-10 aryl, and C 1-4 alkylene-(5-6 membered heteroaryl);

R 7 is selected from H, C 1-4 alkyl, and C 1-4 haloalkyl;

R 8 is selected from H, C 1-4 alkyl, and C 1-4 haloalkyl;

R 9 is selected from H, C 1-6 alkyl, —C 1-4 alkylene-NR a1 R a2 , —C 1-4 alkylene-C(O)NR a1 R a2 , —C 1-4 alkylene-O—C(O)—C 1-4 alkyl, —C 1-4 alkylene-O—C(O)—O—C 1-4 alkyl, —C 1-4 alkylene-O—C(O)—C 1-4 alkylene-NR a1 R a2 , —C 1-4 alkylene-O—C 1-4 alkyl, C 3-8 cycloalkyl, —C 1-4 alkylene-C 3-8 cycloalkyl, 4-6 membered heterocyclyl, and —C 1-4 alkylene-(4-6 membered heterocyclyl);

wherein each C 3-8 cycloalkyl, —C 1-4 alkylene-C 3-8 cycloalkyl, 4-6 membered heterocyclyl and —C 1-4 alkylene-(4-6 membered heterocyclyl) of R 9 is optionally substituted with one to three groups independently selected from halo, C 1-4 alkyl, C 1-4 alkoxyl, and C 1-4 haloalkyl; or

R 9 together with the N that attaches to R 8 forms a 5 membered heterocyclyl; wherein the 5 membered heterocyclyl is optionally substituted with one to two groups independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, C 1-6 haloalkyl, and C 6-10 aryl; wherein C 6-10 aryl is optionally substituted with one to three groups independently selected from halo, C 1-6 alkyl, C 1-6 alkoxyl, and C 1-6 haloalkyl;

each R 10 is independently selected from H, halo, cyano, hydroxyl, —C(O)R b1 , —NR a1 R a2 , C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, and 5-6 membered heteroaryl; wherein each C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8-membered heterocyclyl, C 6-10 aryl, and 5-6 membered heteroaryl is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl;

or two R 10 either attached to the same or adjacent atoms form C 3-12 cycloalkyl or 3-10 membered heterocyclyl; wherein each C 3-12 cycloalkyl and 3-10 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl;

each R 11 is independently selected from H, C 1-4 alkyl, and C 1-4 haloalkyl; wherein each C 1-4 alkyl, —C(O)R b1 , and C 1-4 haloalkyl of R 11 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl;

or R 10 and R 11 , or two R 11 together with the atoms to which they are attached to form 3-12 membered heterocyclyl; wherein 3-12 membered heterocyclyl is optionally substituted with one to three groups independently selected from H, halo, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, and C 1-4 haloalkoxyl;

each R a1 and R a2 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl;

n is selected from 1, 2, and 3;

m is selected from 0, 1, and 2; and

v is selected from 1 and 2.

2. The compound of claim 1 , wherein the ring formed by Y and Z is selected from:

wherein * indicates a point of attachment to R 1 ;

wherein each group is optionally substituted with 1 to 7 R 10 ; and

wherein each R 10 is independently selected from halo, cyano, hydroxyl, C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, 5-6 membered heteroaryl, and —NR a1 R a2 ; wherein each C 1-4 alkyl, C 1-4 alkoxyl, C 1-4 haloalkyl, C 1-4 haloalkoxyl, C 3-10 cycloalkyl, 3-8 membered heterocyclyl, C 6-10 aryl, and 5-6 membered heteroaryl of R 10 is independently optionally substituted with one to three groups independently selected from halo, hydroxyl, cyano, —NR a1 R a2 , C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, and C 3-6 cycloalkyl.

3. The compound of claim 1 , of Formula (II)

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , of Formula (III)

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from phenyl, naphthyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, isoxazolyl, triazolyl, pyrazolyl, benzothiazolyl, pyridinonyl, quinolinonyl, isoquinolinonyl, quinazolindionyl, pyrazinonyl, pyrimidinonyl, pyrimidinedionyl, pyridazinonyl, quinazolinonyl, benzofuranyl, tetrahydrocyclopenta[b]pyridinonyl, naphthyridinonyl, chromanyl, isochromanyl, and chromenonyl, and wherein each R 1 is independently optionally substituted with one to four R a .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from:

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from

wherein each R 4 is optionally substituted with one to two groups independently selected from F, Cl, cyano, hydroxyl, NH 2 , —CH 3 , —CH(CH 3 ) 2 , —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CH 2 F, —CH 2 CHF 2 , —CH 2 CF 3 , C 3-6 cycloalkyl, and —CH 2 C 3-6 cycloalkyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from H, methyl, ethyl, propyl, butyl, —CH 2 C(O)N(CH 3 ) 2 , —(CH 2 ) 2 N(CH 2 CH 3 ) 2 , —CH 2 —O—C(O)CH 3 , —(CH 2 ) 2 —O—C(O)CH 3 , —CH 2 —O—C(O)C(CH) 3 , —(CH 2 ) 2 —O—C(O)C(CH) 3 , —CH 2 —O—C(O)—O—CH 3 , —CH 2 —O—C(O)—O—CH 2 CH 3 , —CH 2 —O—C(O)—O—CH(CH 3 ) 2 , —CH 2 —O—C(O)—O—C(CH 3 ) 3 , —(CH 2 ) 2 C(O)CH 3

11. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 9 is selected from H, methyl, and ethyl.

12. The compound of claim 1 , having the structure of Formula (IIb):

or a pharmaceutically acceptable salt thereof, wherein:

W 1 is selected from CR 31 and N;

W 2 is selected from CR 31 R 31 , NR 32 , O, and S(O) 2 ;

each R 31 is independently selected from H and R b ;

R 32 is selected from H, C 1-4 alkyl, and C 1-4 haloalkyl;

q is selected from 0, 1, 2, and 3; and

t is 0 or 1.

13. The compound of claim 1 , having the structure of Formula (IIIa):

or a pharmaceutically acceptable salt thereof.

14. A compound or a pharmaceutically acceptable salt thereof, selected from:

15. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from:

16. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

17. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 , further comprising at least one or more additional therapeutic agents.

19. A method for treating an inflammatory disease or condition mediated by α4β7 integrin comprising administrating to a subject an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 18 , wherein the at least one or more additional therapeutic agents are independently selected from JAK tyrosine kinase inhibitors, Tumor Progression Locus 2 (TPL2) inhibitors, and IRAK4 inhibitors.

21. The pharmaceutical composition of claim 20 , wherein the additional therapeutic agent is a JAK tyrosine kinase inhibitor, and wherein the JAK tyrosine kinase inhibitor is filgotinib.